Key Highlights

  • Chemed (NYSE:CHE) reports third-quarter results after the close on Tuesday, October 27, 2026, with consensus adjusted earnings of USD 6.44 per share in market data and a hospice recovery in focus.
  • In July the company raised 2026 adjusted earnings guidance to USD 25.00 to USD 25.75 per share, against a prior consensus near USD 24.34, after second-quarter earnings rose about 43.7%.
  • The Vitas hospice unit drove the second-quarter rebound, while the Roto-Rooter plumbing and drain cleaning unit supplies a steadier, weather-linked earnings stream that investors will also track.
  • The Federal Reserve decides on Wednesday, October 28, 2026, a day after the report, after raising rates to a range of 3.75% to 4.00% on Wednesday, September 16, 2026.

The Setup and the Guidance Bar

Chemed (NYSE:CHE) owns Vitas, a hospice and palliative care provider, and Roto-Rooter, a plumbing and drain cleaning business, and it reports third-quarter results after the close on Tuesday, October 27, 2026. Consensus adjusted earnings are USD 6.44 per share, and the company has a market value near USD 6.79 billion. In the company's release of Wednesday, July 29, 2026, second-quarter earnings rose about 43.7% on a hospice rebound, and full-year adjusted earnings guidance was lifted to USD 25.00 to USD 25.75 per share. The earlier consensus for the year was near USD 24.34. Results cannot be known in advance.

Why Hospice Volumes Drive the Quarter

Chemed (NYSE:CHE) earns most of its profit from Vitas, where revenue depends on the number of patients cared for each day and on fixed daily Medicare payment rates. Admissions and length of stay therefore matter more than price, and a recovery in patient census lifts margins because staffing costs are largely fixed. The second-quarter report described a hospice rebound as the main reason for the earnings beat, so investors will test whether admissions kept improving through the third quarter. Roto-Rooter adds a second driver, as demand for drain and plumbing work follows weather, housing activity and the pace of technician hiring. Reimbursement policy from the Centers for Medicare and Medicaid Services remains the reference point for hospice economics, because it sets the annual rate update.

Risks and What to Watch

The bull case for Chemed (NYSE:CHE) is earnings above USD 6.44 with hospice census growth sustained and guidance lifted again toward the top of the USD 25.00 to USD 25.75 range. That would confirm that the July recovery was durable, and shares would likely respond favourably because a rebound is already partly expected. The bear case is a quarter that meets the consensus while the company holds the range, or one that shows slower admissions, since a raised outlook leaves less room for disappointment. Weakness in Roto-Rooter job counts or higher labour costs could also cap the result. Investors should watch Vitas admissions and average daily census, margins, the year guidance and commentary on Medicare rates.

Where Things Stand

The answer is that Chemed (NYSE:CHE) reports against a USD 6.44 consensus with a raised USD 25.00 to USD 25.75 full-year range already on the table, so hospice census trends and any change to that range will likely matter more than the quarterly figure. The next catalysts are the release after the close on Tuesday, October 27, 2026, the Federal Reserve decision on Wednesday, October 28, 2026 and the first full session of trading after the report. Consensus figures are estimates, not guarantees, and this is not investment advice.